Hosted on MSN6mon
FDA approves new COPD drug developed by firm in Raleigh. First new treatment in a decadeVerona Pharma will market ensifentrine under the brand name Ohtuvayre. Chronic obstructive pulmonary disease (COPD) makes it harder for your lungs to function, leading to shortness of breath and ...
The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...
The company's current product candidate and potential value creator is ensifentrine (commercially "Ohtuvayre"), an inhaled and dual inhibitor that acts as both a bronchodilator and an anti ...
“We are pleased to report an exceptionally strong start to the US launch of Ohtuvayre (ensifentrine) with healthcare professionals (HCPs) prescribing treatment across a broad range of chronic ...
Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...
LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10 ...
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
Net Product Sales: $5.6 million for Ohtuvayre in the third quarter. Cost of Goods Sold: $500,000 for the quarter ended September 30, 2024. Research and Development Costs: $10.6 million for the quarter ...
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback